Untested combination Skin and Hair
Melanotan II + PT-141 (stack)
Also called MT-II/PT-141
A pairing of two melanocortin-receptor peptides sold as separate vials. Melanotan II is an unapproved tanning peptide with serious safety warnings; PT-141 is approved only as Vyleesi for a specific condition in premenopausal women. The combination has not been studied.
Overview
What it is
Melanotan II and bremelanotide (PT-141). See each entry.
How it works
Both act on melanocortin receptors, which affect pigmentation, appetite, nausea, blood pressure and sexual response. Stacking them adds overlapping effects.
What the research shows
No study of the combination was identified.
Studied for
- None as a combination.
Safety and regulatory status
Safety and side effects
Overlapping side effects include nausea, flushing, blood pressure changes and skin darkening. Melanotan II carries regulatory warnings about moles, kidney problems and brain swelling. A prolonged erection is an emergency.
Regulatory status
Melanotan II is unapproved; PT-141 is approved only as Vyleesi for HSDD in premenopausal women.
Mixing and dosing reference
Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.
PT-141 (10 mg) + Melanotan II (10 mg) Stack Dosage Protocol
- Vial
- 10 mg
- Add diluent
- 3 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg in 0.01 mL
- Route
- Subcutaneous
Combined Component Schedule (each 10 mg vial prepared separately with 3 mL)
| Component | Period / Phase | Amount per Administration | U-100 Units (mL) |
|---|---|---|---|
| PT-141 | Initial / Titration | 500–750 mcg | 15–22 units (0.15–0.22 mL) |
| PT-141 | Standard | 1,000–1,500 mcg | 30–45 units (0.30–0.45 mL) |
| PT-141 | Full / FDA-approved product amount | 1,750 mcg (1.75 mg) | 52 units (0.52 mL) |
| Melanotan II | Week 1 | 250 mcg | 7.5 units (0.075 mL)* |
| Melanotan II | Week 2 | 500 mcg | 15 units (0.15 mL) |
| Melanotan II | Weeks 3–4 | 750 mcg | 22 units (0.22 mL) |
| Melanotan II | Weeks 5+ loading | 1,000 mcg | 30 units (0.30 mL) |
| Melanotan II | Maintenance | 500–1,000 mcg | 15–30 units (0.15–0.30 mL) |
How to mix
- Confirm the correct PT-141 or Melanotan II vial and clean its stopper.
- Draw 3.0 mL bacteriostatic water and add it slowly down the wall of that vial.
- Gently swirl or roll until fully dissolved; do not shake.
- Label the vial with peptide name, concentration, and preparation date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Key differences between the two peptides.
- PT-141: Start at 500–750 mcg; titrate to 1750 mcg as tolerated. On-demand use only; max 8 doses/month.
- Melanotan II: Start at 250 mcg daily; increase by 250 mcg every 5–7 days to target 1000 mcg. Transition to maintenance after desired effect.
- Timing: PT-141 at least 45 min before activity; Melanotan II at any consistent time daily.
- Sites: Rotate injection sites (abdomen, thighs) for both.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; use each vial’s product-specific labeled storage conditions.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow a validated use-by period for each separately prepared vial.
- Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.
Administration technique
- Clean the vial stopper with an alcohol swab; allow to dry completely.
- Clean the injection site (abdomen or thigh) with an alcohol swab for at least 30 seconds; allow to dry.
- Pinch a fold of skin; insert the needle at 45–90° depending on subcutaneous tissue depth.
- Aspiration is not required for subcutaneous injections; inject slowly and steadily.
- Release the skin fold, withdraw the needle, and apply gentle pressure if needed.
- Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy or irritation.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document each dose, time, and injection site to maintain consistency.
- PT-141: Do not exceed 8 doses per month or 1 dose per 24 hours.
- Melanotan II: UV exposure (sun or controlled tanning) during use may enhance pigmentation effects; appropriate sun protection is advised.
Protocol source: PeptideDosages.com
Common questions
Is it safe to combine them?
The combination has not been studied, and their effects overlap.
Related in Skin and Hair
Sources and further reading (3)
- DailyMed. Vyleesi prescribing information.
- TGA. Don't risk using tanning products containing melanotan, 2025.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.